Gravar-mail: Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine: A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)